CellProthera Partners with CELLforCURE by SEQENS for Phase 3 Manufacturing of Heart Attack Cell Therapy
CellProthera has selected CELLforCURE by SEQENS as its CDMO partner for Phase 3 manufacturing of ProtheraCytes, an autologous expanded CD34+ stem cell therapy for severe heart attack patients.
CellProthera Initiates Long-Term Study of ProtheraCytes for Acute Myocardial Infarction
CellProthera has begun the PERFECT study, a 10-year observational follow-up to assess ProtheraCytes' long-term safety and efficacy after acute myocardial infarction.
CellProthera Advances ProtheraCytes Cell Therapy Program for Myocardial Infarction with FDA Alignment on Phase III Trial Design
CellProthera has secured FDA alignment on the design for a pivotal Phase III trial of ProtheraCytes, a cell therapy for acute myocardial infarction (AMI).
© Copyright 2025. All Rights Reserved by MedPath